Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 11 , ISSUE 6 ( November-December, 2019 ) > List of Articles


Novel Therapies in Management of Stress Urinary Incontinence

Bhadana Priyanka, Kiran Abha, Khandelwal Madhu

Keywords : Genital prolapse, Incontinence, Levator ani, Menopausal problems, Pelvic floor dysfunctions, Pelvic floor muscle exercise, Pelvic organ prolapse, Stress, Urodynamic studies

Citation Information : Priyanka B, Abha K, Madhu K. Novel Therapies in Management of Stress Urinary Incontinence. J South Asian Feder Obs Gynae 2019; 11 (6):385-388.

DOI: 10.5005/jp-journals-10006-1730

License: CC BY-NC 4.0

Published Online: 25-04-2013

Copyright Statement:  Copyright © 2019; The Author(s).


Female urinary incontinence (UI) is a common problem affecting 40% of women, but it is usually understated. It not only is a medical problem but has a larger impact on a women’s social and psychological life. It is often not reported by women especially Indian women as they tend to accept it as a part of aging or a consequence of childbirth. In this review, we would be focusing on female stress UI (SUI) and newer therapies that can help improve the symptoms and lifestyle of such women. Pregnancy, childbirth, menopause, obesity, advanced age, and race and ethnicity are some common risk factors for SUI. The underlying mechanism includes pudendal nerve denervation, loss of ligamentous support of the urethral complex leading to dysfunction of the levator ani muscles, endopelvic fascia, and muscular urethra causing UI. Many treatment options are available for treating UI, such as lifestyle changes, pelvic floor muscle training (PFMT), bladder training, and electromagnetic stimulation of the pelvic floor muscles, and the surgical procedures—Burch colposuspension and bladder‐neck slings and their various modifications. Traditionally, surgery forms the mainstay of management but now focus is towards minimally invasive and non-surgical techniques which could improve the quality of life in such patients. Newer therapies for SUI Management includes the drug-duloxetine, laser therapy and stem cell therapy.

  1. MacLennan AH, Taylor AW, Wilson DH, et al. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. BJOG 2000;107(12):1460–1470. DOI: 10.1111/j.1471- 0528.2000.tb11669.x.
  2. Castro RA, Arruda RM, Bortolini MAT. Female urinary incontinence: effective treatment strategies. Climacteric 2014;17:1–7.
  3. Norton P, Brubaker L. Urinary incontinence in women. Lancet 2006;367(9504):57–67. DOI: 10.1016/S0140-6736(06)67925-7.
  4. Shukui Z, Kaile Z, Anthony A, et al. Stem cell therapy for treatment of stress urinary incontinence: the current status and challenges. Stem Cells Int 2016;2016:7060975. DOI: 10.1155/2016/7060975.
  5. Hardy LA, Chang CH, Myers EM, et al. Laser treatment of female stress urinary incontinence: optical, thermal, and tissue damage simulations. In: Photonic Therapeutics and Diagnostics XII. San Francisco, United States: SPIE, Photonic Therapeutics and Diagnostics XII; 2016. vol. 9689; 96891R 10.1117/12.2208126.
  6. Singh A, Swift S, Khullar V, et al. Laser vaginal rejuvenation: not ready for prime time. Int Urogynecol J 2015;26(2):163–164. DOI: 10.1007/ s00192-014-2588-2.
  7. Arunkalaivanan A, Kaur H, Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J 2017;28(5):681–685. DOI: 10.1007/s00192-017-3282-y.
  8. Pergialiotis V, Prodromidou A, Perrea DN, et al. A systematic review on vaginal laser therapy for treating stress urinary incontinence: do we have enough evidence? Int Urogynecol J 2017;28(10):1445–1451. DOI: 10.1007/s00192-017-3437.x.
  9. Okui N. Comparison between erbium-doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence. World J Urol 2018;37(5):885–889. DOI: 10.1007/s00345-018-2445-x.
  10. Blaganje M, Šæepanoviæ D, Žgur L, et al. Non-ablative Er:YAG laser therapy effect on SUI related quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Bio 2018;224:153–158. DOI: 10.1016/j.ejogrb.2018.03.038.
  11. Cardozo L. New developments in the management of stress urinary incontinence. BJU Int 2004;94(s1):1–3. DOI: 10.1111/j.1464- 410X.2004.04807.x.
  12. Vizintin Z, Lukac M, Kazic M, et al. Erbium laser in gynecology, Climacteric 2015;18(Supp 1):4–8. DOI: 10.3109/13697137.2015.1078668.
  13. Gambacciani M, Levancini M. Short-term effect of vaginal erbium laser on the genitourinary syndrome of menopause. Minerva Ginecol 2015;67(2):1–2.
  14. Carr LK, Steele D, Steele S, et al. 1-Year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008;19(6): 881–883. DOI: 10.1007/s00192-007-0553-z.
  15. Pergialiotis V, Prodromidou A, Perrea DN, et al. A systematic review on vaginal laser therapy for treating stress urinary incontinence: Do we have enough evidence? Int Urogynecol J 2017;28(10):1445–1451. DOI: 10.1007/s00192-017-3437-x.
  16. Blaganje M, Lukanovic A. Intrasphincteric autologous myoblast injections with electrical stimulation for stress urinary incontinence. Int J Gynaecol Obstet 2012;117(2):164–167. DOI: 10.1016/ j.ijgo.2011.11.029.
  17. Blaganje M, Šæepanoviæ D, Žgur L, et al. Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2018;224:153–158. DOI: 10.1016/ j.ejogrb.2018.03.038.
  18. Peters KM, Dmochowski RR, Carr LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol 2014;192(2):469–476. DOI: 10.1016/j.juro.2014.02.047.
  19. Thor K, Katofiasc M. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anaesthetized female cat. J Pharmacol Exp Ther 1995;274(2):1014–1024.
  20. Ghoniem GM, Van Leeuwen JS, Elser DM, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 2005;173(5):1647–1653. DOI: 10.1097/01. ju.0000154167.90600.c6.
  21. Vizintin Z, Rivera M, Fistoniæ I, et al. Novel minimally invasive VSP er:YAG laser treatments in gynecology. J Laser and Health Acad 2012;1(1):46–58.
  22. Tien YW, Hsiao SM, Lee CN, et al. Effects of laser procedure for female urodynamic stress incontinence on pad weight, urodynamics, and sexual function. Int Urogynecol J 2017;28(3):469–476. DOI: 10.1007/ s00192-016-3129-y.
  23. UB1 Ogrinc, Senèar S, Lenasi H. Novel minimally invasive laser treatment of urinary incontinence in women. Lasers Surg Med 2015;47(9):689–697. DOI: 10.1002/lsm.22416.
  24. Carr LK, Robert M, Kultgen PL, et al. Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. J Urol 2013;189:595.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.